- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Recombinant human cerebral dopamine neurotrophic factor
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Recombinant human cerebral dopamine neurotrophic factor
| EU orphan designation number: | EU/3/16/1652
|
| Active ingredient: | Recombinant human cerebral dopamine neurotrophic factor |
| Indication: | Treatment of amyotrophic lateral sclerosis |
| Sponsor: | Herantis Pharma Plc
Viikinkaari 4, 00790 Helsinki, Finland |
Public summary of scientific opinion
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 02/05/2016 | Orphan designation | EMA/OD/241/15 | (2016) 2749 of 28/04/2016 |
CONTACT
EU links
Directorate General Health & Consumers